BioStock: The pieces fell into place for Dicot in Q2

Uppsala-based Dicot continues to take decisive steps in the development of LIB-01. The phase I study with the drug candidate has now started. In the latest quarterly report, CEO Elin Trampe expresses her enthusiasm for the milestone. BioStock took the opportunity to contact Trampe in connection with the report for her view on the autumn.

Read the full article at biostock.se:

https://www.biostock.se/en/2023/08/the-pieces-fell-into-place-for-dicot-in-q2-ceo/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se